City
Epaper

Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. launch Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg in U.S. market

By ANI | Updated: March 17, 2022 20:30 IST

Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. today announced the launch of Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of the reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, Inc. in the U.S. market. The product will be distributed by Seton Pharmaceuticals, LLC.

Open in App

Seton Pharmaceuticals, LLC and Senores Pharmaceuticals, Inc. today announced the launch of Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg, a therapeutic equivalent of the reference listed drug Butalbital, Acetaminophen, and Caffeine capsules of Mayne Pharma, Inc. in the U.S. market. The product will be distributed by Seton Pharmaceuticals, LLC.

Butalbital, Acetaminophen and Caffeine Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.

"We are pleased to collaborate with Seton Pharmaceuticals for the commercial launch of Butalbital, Acetaminophen and Caffeine Capsules in the U.S. market" stated Dhananjay Barot, Director, Senores Pharmaceuticals, Inc. "Our unfaltering adherence towards the pharmaceutical industry makes us a major supplier for this product" stated Swapnil Shah, Managing Director, Senores Group.

"Seton is proud to partner with Senores on the launch of Butalbital, Acetaminophen and Caffeine Capsules" stated Christopher McCarthy, Executive Vice President of Seton Pharmaceuticals, LLC. "This continues our commitment to providing affordable medicines to the consumer through quality manufacturing partnerships."

U.S. annual market size for Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/325 mg/40 mg was approximately USD 29.18 million (Symphony, Dec 2021).

Seton Pharmaceuticals, LLC was established in 2007 in Wall Township, New Jersey. Focusing on FDA approved generic pharmaceuticals, Seton partners with developers and manufacturers to launch ANDA products under the Seton label. With a strong emphasis on product & financial management and supplier & customer service, Seton delivers unparalleled product quality.

Senores Pharmaceuticals, based in Atlanta, Georgia is one of the fastest-growing pharmaceutical companies in the U.S. market. Currently, the company has more than 15 products commercially launched or filed with the USFDA.

Seton Pharmaceuticals, LLC1967 Highway 34Wall Township New Jersey 07719800-510-3401

Senores Pharmaceuticals, Inc. Atlanta,Georgia

Photo:

This story is provided by PRNewswire.will not be responsible in any way for the content of this article. (ANI/PR Newswire)

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: HomoSeton pharmaceuticalsDhananjay barotSwapnil shahAtlantaLLCDianne mcgunigle
Open in App

Related Stories

NationalIndia-Pakistan Ceasefire: Donald Trump Claims the US Administration Stopped Nuclear War

International‘Not Going To Get Involved in Middle of War’: JD Vance Over India-Pakistan Tensions

NationalOperation Sindoor: PM Narendra Modi Calls For All-Party Meeting On May 8 After India Strikes On Pakistan Terror Camps

InternationalColorado Nightclub Raid: Over 100 Illegal Immigrants Detain at Underground Nightclub in US; Video Surfaces

BusinessGlobal Tech Firms Eye India for Manufacturing Amid US-China Tensions

Business Realted Stories

BusinessIndia-made defence systems now a formidable force in 21st-century warfare: PM Modi

BusinessTariff gap that once favoured India is shrinking fast after latest US-China deal: Expert Ajay Srivastava

BusinessUS stocks soar as tariff truce with China sparks global market rally

BusinessUnion Minister Manohar Lal, Goa CM Sawant review progress of urban development schemes

BusinessRaymond Lifestyle suffers Rs 45 crore net loss in Q4; revenue and margins take a hit